HDAC1 and neoplasm: Additionally, in vivo, St.5 significantly reduced tumor growth (by 75%) in PC3 xenograft models without evident toxicity, highlighting it as a promising selective HDAC1 inhibitor for advanced prostate cancer therapy [95].